The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection

Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann. Intern. Med. 2015;162(9):619-629.

Publication Type:

Journal Article

Authors:

Linas, B.P.; Barter, D.M.; Morgan, J.R.; Pho, M.T.; Leff, J.A.; Schackman, B.R.; Horsburgh, C.R.; Assoumou, S.A.; Salomon, J.A.; Weinstein, M.C.; Freedberg, K.A.; Kim, A.Y.

Source:

Ann. Intern. Med, Volume 162, Issue 9, p.619-629 (2015)

Keywords:

analogs & derivatives, analysis, Antiviral Agents, complications, Cost-Benefit Analysis, Disease, Disease Progression, drug therapy, economics, etiology, genetics, Genotype, HCV, Health, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, history, Humans, Infection, interferon, Interferon-alpha, Liver Cirrhosis, Markov Chains, Monte Carlo Method, Patients, pegylated, PROVIDE, Quality-Adjusted Life Years, Research, Research Support, Ribavirin, sofosbuvir, therapeutic use, therapy, Time, transmission, treatment, treatment-naive, United States, Uridine, Uridine Monophosphate

Notes:

PMC4420667

Cited On:

Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25820703

Export Citation:

RIS Format

Top